Oral Tirzepatide and the Adherence Problem: Why Non-Injectable GLP-1 Formats Are Drawing Attention

Roughly half of patients with chronic conditions in developed countries do not take their medicines as recommended, according to the World Health Organization’s landmark report Adherence to Long-Term Therapies: Evidence for Action. Two decades later, that finding still frames almost every conversation about long-term prescriptions, and it has taken on new weight as GLP-1 receptor agonists move from specialist clinics into mainstream primary care. When a therapy is designed to be taken for months or years, the question of whether patients can realistically keep taking it matters as much as the pharmacology itself.

That is the backdrop against which interest in non-injectable formats, including oral tirzepatide preparations, has grown. The shift is less about novelty than about a long-standing truth in medicine: the most carefully chosen therapy delivers nothing if it sits unused in a refrigerator.

The scale of the adherence gap

The cost of non-adherence is not abstract. The New England Healthcare Institute estimated in its 2009 report “Thinking Outside the Pillbox” that poor medication adherence costs the US health system about $290 billion a year in avoidable spending. Research published in the Journal of General Internal Medicine by Fischer and colleagues in 2010 found that 20 to 30 percent of new prescriptions in the United States are never filled at a pharmacy at all.

Meanwhile, the population for whom weight-related prescriptions may be considered is large. The CDC’s National Center for Health Statistics reported that 40.3 percent of US adults had obesity in the August 2021 to August 2023 survey period, with prevalence peaking at 46.4 percent among adults aged 40 to 59. Uptake of GLP-1 medicines has followed. A KFF Health Tracking Poll conducted in spring 2024 found that 12 percent of US adults said they had ever taken a GLP-1 drug, and 6 percent said they were currently taking one.

Put those figures side by side and the challenge becomes clear. Millions of people are starting long-term therapies, and the historical baseline suggests a substantial share will struggle to stay on them as prescribed.

Why the delivery format matters

Adherence researchers generally group barriers into a few categories: cost, side effects, complexity of the regimen, forgetfulness, and the patient’s own beliefs and feelings about the treatment. The route of administration touches several of these at once.

Needle anxiety is common and under-reported

A widely cited 1995 paper by Hamilton in the Journal of Family Practice estimated that at least 10 percent of American adults experience some degree of fear of needles, and the author argued the true figure was likely higher because people with severe fear tend to avoid medical settings entirely. Under the stricter clinical definition of blood-injection-injury phobia, a 2014 review by Wani, Ara and Bhat in Behavioural Neurology put prevalence at around 3 to 4 percent of the general population.

Even mild discomfort can shape behaviour over time. A weekly injection that feels like a small hurdle in month one can become a reason to postpone a dose in month six. For patients with a genuine phobia, an injectable regimen may never begin at all.

Routine and habit formation

Behavioural scientists often point out that daily habits anchored to an existing routine, such as brushing teeth or a morning coffee, are easier to maintain than weekly tasks that must be remembered separately. Injectable GLP-1 therapies are commonly dosed once weekly, which some patients find convenient and others find easy to forget. Daily oral formats change that rhythm. Whether daily or weekly dosing suits a given person better is an individual question that clinicians weigh case by case, but the existence of choice is itself meaningful for adherence.

Storage, handling and the friction of preparation

Injectable peptide medications typically require refrigeration and careful handling, along with sharps disposal. Each of these is a small friction point. Non-injectable formats can reduce some of that handling burden, though storage requirements vary by formulation and pharmacy, and patients are expected to follow the specific instructions dispensed with their prescription.

The prescriber’s role in matching format to patient

Format preferences only matter if they are surfaced. Clinicians increasingly ask about needle comfort, daily routines and storage at home during the initial assessment, rather than assuming a single default. That conversation also covers medical history, current medicines and any conditions that would make a particular therapy inappropriate. A patient who strongly prefers a needle-free option may still be better served by another approach, and the reverse can also be true. The point is that adherence starts with a shared, realistic plan rather than a prescription the patient privately doubts they will follow.

How the market is responding

The direction of travel across the industry is unmistakable. Drug developers, compounding pharmacies and telehealth providers have all been exploring how peptide and non-peptide therapies can be delivered without a needle.

It is important to separate these categories clearly. A commercially manufactured tablet that has completed the full regulatory pathway is a different product from a compounded oral preparation made by a licensed pharmacy for an individual patient. Compounded medications are not approved by the FDA and do not go through its premarket review for safety, effectiveness or quality, and they are prescribed only when a licensed clinician determines they are appropriate for a specific person. Clinicians consider factors such as medical history, other medications, and how a patient has responded to previous treatment before recommending any format.

What research is exploring

Oral delivery of peptides is technically demanding. Large molecules tend to be broken down in the digestive tract and absorbed poorly, which is why many peptide therapies were historically injected. Research is exploring absorption enhancers, sublingual and buccal routes that bypass part of the digestive process, and small-molecule alternatives that behave differently from peptides. Much of this work is ongoing, and the evidence base for specific compounded oral preparations remains less developed than for established injectable forms. That is one reason prescribers emphasise individual assessment and follow-up rather than one-size-fits-all recommendations.

How it works in practice

For patients, the practical pathway to a non-injectable option increasingly runs through direct-to-consumer telehealth. HealSend, a US telehealth platform, illustrates the typical model. A patient completes an online intake form covering health history, and a licensed US medical provider reviews it and determines whether a personalized treatment plan is appropriate. The platform’s eligibility questions screen for conditions such as kidney disease, type 1 diabetes and a history of medullary thyroid cancer, and the intake is limited to adults within a defined age range.

Among the formats it lists is oral tirzepatide, described on its site as a needle-free daily option that is compounded by a licensed US pharmacy. The company states that this preparation is prescribed only after one of its clinicians reviews the patient’s health history, and it notes plainly that compounded medications are prescribed only when a licensed clinician determines they are appropriate. Prescriptions ship to the patient’s home in discreet packaging, and the service operates only within the United States, with availability subject to state rules. HSA and FSA cards are accepted at checkout, and the plans are cash-pay and month-to-month.

The model reflects the broader adherence argument. It does not change the underlying medicine, but it lowers several practical barriers at once: no clinic visit, no needle for patients who are prescribed an oral format, and refills that are coordinated rather than left for the patient to remember.

Friction points that remain

Non-injectable formats do not solve adherence on their own, and it would be a mistake to frame them that way.

• Daily dosing cuts both ways. A daily format can anchor to routine, but it also creates seven opportunities a week to miss a dose instead of one.
• Side effects still drive discontinuation. Gastrointestinal effects are well documented across the GLP-1 class regardless of format, and tolerability remains one of the main reasons people stop.
• Cost is a persistent barrier. The same 2024 KFF poll found that 54 percent of adults who had taken GLP-1 drugs said the cost was difficult to afford. Format convenience cannot offset a price a patient cannot keep paying.
• Evidence varies by product. Patients and prescribers need to understand which formats have been studied extensively and which are newer or compounded, so that expectations are set realistically.

What comes next

Several trends are likely to shape the next phase. First, more delivery formats are coming. Patients and prescribers have shown they want options beyond the weekly pen, and research into oral and sublingual peptide delivery is continuing.

Second, adherence support is moving from the pharmacy counter into software. Refill coordination, reminders and asynchronous messaging with clinicians are becoming standard parts of telehealth programs, and these tools target forgetfulness and access issues that the WHO identified more than twenty years ago.

Third, regulators and payers are paying closer attention to compounding, quality controls and how formats are described to consumers. Clear, accurate labelling and honest framing of what is and is not established will matter for patient trust.

Conclusion

The renewed interest in non-injectable GLP-1 formats is ultimately an adherence story. Decades of data show that half of patients with chronic conditions struggle to follow long-term regimens, and that barriers such as needle anxiety, handling requirements and cost erode persistence over time. Oral and sublingual formats address some of those barriers, though not all, and the evidence behind each preparation varies. For patients weighing their options, the most useful frame is not which format is newest but which one they are realistically able to keep taking, a decision that belongs in a conversation with a licensed clinician who can assess eligibility, risks and fit.